NewLimit, a South San Francisco-based longevity biotechnology company, has secured $435 million in Series C financing, bringing its total capital raised to over $700 million and its valuation to approximately $3.1 billion. Led by Founders Fund, the round included participation from high-profile investors like Thrive Capital, Greenoaks, and Eli Lilly Ventures. This funding is strategically earmarked to accelerate the company’s transition from early-stage discovery to clinical development.

NewLimit is pioneering epigenetic reprogramming, utilizing its proprietary AI platform, Ambrosia, to identify transcription factor combinations that reset aged cells to a youthful state while preserving their cellular identity. The company now plans to enter first-in-human clinical trials next year, a timeline significantly faster than its initial 10-year projection. Its lead program is a liver-directed mRNA therapy designed to reverse cellular age in hepatocytes, aiming to restore regenerative capacity in patients suffering from metabolic damage or injury. Beyond this, NewLimit is actively expanding its pipeline into vascular and immune health.

In a strategic move to reclaim the US lead in clinical research, the Department of Health and Human Services (HHS) has initiated "Operation Trailblazer." This comprehensive effort aims to reverse the trend of early-stage trials migrating overseas by reducing regulatory timelines by six to 12 months. The FDA is spearheading several reforms, including an Expedited Investigational New Drug (IND) pilot program that leverages partnerships with research institutions to streamline Phase 1 submissions. Additionally, the agency is promoting the use of Quantitative Systems Pharmacology (QSP) to move away from animal-based dosing models and has clarified phase-specific Chemistry, Manufacturing, and Controls (CMC) requirements to eliminate unnecessary data burdens. By launching a dedicated "Phase 1 IND Navigator" and a specialized contact center, the FDA intends to lower barriers for smaller biotech firms, ensuring that the US remains the premier environment for transformative medical innovation.

For 20 years, Prix Galien USA has honored the breakthroughs shaping the future of healthcare and improving lives worldwide. Often regarded by the industry as the equivalent of the Nobel Prize of biopharmaceutical research, this is where innovation meets impact.

From groundbreaking therapies to life-saving technologies, this is more than an event, it’s a global movement advancing human health.

Follow The Galien Foundation on LinkedIn to stay updated on announcements, speakers, and innovations leading up to the event.

Biotech innovators Circio Holding ASA and Tcelltech GmbH have entered a research collaboration to revolutionize engineered T-cell therapies. By integrating Circio’s stable circular RNA (circVec) expression platform with Tcelltech’s high-capacity, non-viral nanoSMAR DNA vector, the companies aim to overcome the limitations of current viral-based CAR-T approaches. Current ex vivo manufacturing is costly and complex, while existing in vivo methods face safety risks regarding genomic integration. This partnership seeks to enable the design of sophisticated, multi-gene constructs that provide safer, more durable, and cost-effective T-cell engineering. The staged research program will initially focus on gene expression durability in primary human T-cells, followed by functional testing of CD19-directed CAR-T cells against tumor targets. This synergy positions both companies to advance the frontier of in vivo cell therapies, potentially making life-saving treatments more scalable and accessible for a broader patient population.

Genflow Biosciences has been invited to present findings from its SLAB (Sarcopenia and Longevity in Aged Beagles) study at the Animal Longevity Summit 2026 in Toronto this October. The study, which concluded in June 2026, evaluated the safety and biological activity of Genflow’s proprietary SIRT6 centenarian gene therapy in aged dogs. As one of the most comprehensive datasets in veterinary longevity research, the presentation is expected to provide key external validation for Genflow’s platform. The data will be scrutinized by leading longevity scientists, potentially serving as a major catalyst for the company’s broader mission to treat age-related decline in both pets and humans. Furthermore, Genflow is strategically transitioning its therapeutic pipeline, including its lead candidate for metabolic dysfunction-associated steatohepatitis (MASH), GF-1002, toward mRNA-LNP technology. This shift aims to facilitate repeat dosing and reduce immunogenicity, strengthening the scientific and commercial case for its human clinical programs.

Parkinson’s disease has no licensed disease-modifying therapies, and clinical trials repeatedly fail to find success. Scientists cannot agree on a cause or even a mechanism of progression, but the issue at the heart of this is that Parkinson’s is being diagnosed too late.

Parkinson’s diagnoses typically occur at the point of obvious symptom development, but these often only appear when a patient has already lost a significant proportion of dopaminergic neurons in their brain. In fact, researchers estimate that neuronal loss may begin up to seven years pre-diagnosis, with an initial decrease in dopaminergic activity as much as 17 years pre-diagnosis1. So are patients entering clinical trials too late? If significant degeneration has already occurred, resulting in symptoms, treatments to slow degeneration are of limited use for truly preserving neurological function.

The key to success in clinical trials may be in the earlier diagnosis of Parkinson’s disease. Parkinson’s has multiple well-documented prodromal features that remain underutilized in diagnosis and clinical trial recruitment: REM sleep behaviour disorder (RBD), where many as 66% of patients are thought to develop Parkinsons’s or a similar synucleinopathy within 8 years2; hyosmia, seen in 50-90% of early-stage Parkinson’s disease3; and chronic constipation, a known risk factor for Parkinson’s and potential predictor of cognitive decline4. These conditions are commonly overlooked in clinical practice, meaning that the prodromal window is repeatedly missed. Systematically screening, recruiting, and investigating people experiencing these symptoms may prove crucial to the early diagnosis of Parkinson’s disease and the future success of clinical trials. The prodromal window may be the most important therapeutic opportunity in Parkinson's research. We are missing it.

References

1. Ramesh S, Arachchige ASPM. Depletion of dopamine in Parkinson’s disease and relevant therapeutic options: A review of the literature. AIMS Neurosci. 2023;10(3):200-231. doi:10.3934/Neuroscience.2023017

2. Postuma RB, Gagnon JF, Bertrand JA, Génier Marchand D, Montplaisir JY. Parkinson risk in idiopathic REM sleep behavior disorder. Neurology. 2015;84(11):1104-1113. doi:10.1212/WNL.0000000000001364

3. Fullard ME, Morley JF, Duda JE. Olfactory Dysfunction as an Early Biomarker in Parkinson’s Disease. Neurosci Bull. 2017;33(5):515-525. doi:10.1007/s12264-017-0170-x

4. Camacho M, Macleod AD, Maple-Grødem J, et al. Early constipation predicts faster dementia onset in Parkinson’s disease. npj Parkinsons Dis. 2021;7(1):45. doi:10.1038/s41531-021-00191-w